Showing 1801-1810 of 2526 results for "".
- Ocuphire Pharma Appoints Joseph K. Schachle COOhttps://modernod.com/news/ocuphire-pharma-reports-inducement-grant-for-new-coo/2481985/Ocuphire Pharma announced that the independent members of its Board of Directors approved an equity award under the company’s 2021 Inducement Plan as a material inducement to Joseph K. Schachle in connection with his employment with Ocuphire effective on November 27, 2023. The equity award
- Berkeley Scientists Discover Retinal Cells that Help Stabilize Our World Viewhttps://modernod.com/news/berkeley-scientists-discover-retinal-cells-that-help-stabilize-our-world-view/2481975/Herbert Wertheim School of Optometry & Vision Science researchers have discovered rare neurons in the eye that are crucial for our visual system to maintain a sharp, steady image of the world. These findings may impact our understanding of the human retina and provide insights
- LENZ Therapeutics and Graphite Bio Announce Mergerhttps://modernod.com/news/lenz-therapeutics-and-graphite-bio-announce-merger/2481971/LENZ Therapeutics and Graphite Bio announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia. The combined company is expected to trade on Nasdaq under the t
- First Patient Dosed in Ocugen's Phase 1/2 Trial Evaluating Safety and Efficacy of OCU41OST Modifier Gene Therapy for Stargardt Diseasehttps://modernod.com/news/first-patient-dosed-in-ocugens-phase-12-trial-evaluating-safety-and-efficacy-of-ocu41ost-modifier-gene-therapy-for-stargardt-disease/2481960/Ocugen announced that the first patient has been dosed in its phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. “There is a significant unmet medical need for the approximate 35,000 patien
- Visionix Announces Strategic Partnership with 20/20NOWhttps://modernod.com/news/visionix-announces-strategic-partnership-with-2020now/2481957/Visionix USA announced it has entered a into a strategic alliance with 20/20NOW with the aim of bringing cost-effective, in-office, synchronous tele-optometry eye exams and ocular telemedicine closer to more patients throughout the United States. Financial terms of the deal we
- Verana Health Partners with Foundation Fighting Blindness to Integrate Genetic Testing Data into Real-World Evidence Researchhttps://modernod.com/news/verana-health-partners-with-foundation-fighting-blindness-to-integrate-genetic-testing-data-into-real-world-evidence-research/2481940/Verana Health and the Foundation Fighting Blindness announced a partnership focused on providing the life sciences community with deeper and broader data to optimize and expedite clinical trials. Under the partnership, the Foundation will provide Verana with de-identified genomics
- Stuart Therapeutics Enters License Agreement with Glaukos for Preclinical Glaucoma Drug Candidatehttps://modernod.com/news/stuart-therapeutics-enters-license-agreement-with-glaukos-for-preclinical-glaucoma-drug-candidate/2481904/Stuart Therapeutics has entered into a license agreement with Glaukos under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a pat
- Pixium Vision Announces the Launch of a Process to Find Buyershttps://modernod.com/news/pixium-vision-announces-the-launch-of-a-process-to-find-buyers/2481900/Pixium Vision SA announced that a tender process (appel d’offres) for the purpose of finding buyers to acquire the company's business will be published October 19. Unable to find financial investors within the restricted timeframe and in line with the company's n
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLshttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols/2481897/Bausch + Lomb announced the launch of the enVista Aspire monofocal and toric IOLs in the United States. The enVista Aspire IOLs featured B+L's Intermediate Optimized (IO) optics, which are designed for a broader depth of focus, with the benefits of the enVista platform to address patient
- SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Diseasehttps://modernod.com/news/splicebio-enters-collaboration-with-spark-therapeutics-to-develop-a-gene-therapy-targeting-an-inherited-retinal-disease/2481894/SpliceBio has announced the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. Under the terms of